GlassScriptPhysician profile
Neil Culligan
NPI 1649275611
$1,517.51
in general payments reported to CMS, 2019-2025
32 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $276 · 2024: $13.20 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $200.16 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $140.54 | 2019-2020 | |
| Argenx US, INC. | $121.19 | 2025 | Vyvgart |
| Eisai INC. | $94.82 | 2019 | |
| Ucb, INC. | $93.88 | 2019 | |
| Lundbeck LLC | $74.70 | 2019-2020 | |
| Grifols USA, LLC | $71.75 | 2019 | |
| Emd Serono, INC. | $71.43 | 2019 | |
| Alexion Pharmaceuticals, INC. | $71.30 | 2019-2020 | |
| Amgen INC. | $55.00 | 2019 | |
| Acadia Pharmaceuticals INC | $53.41 | 2019-2020 | |
| Ge Healthcare | $52.70 | 2019-2020 | |
| Csl Behring | $46.75 | 2019 | |
| Jazz Pharmaceuticals INC. | $34.63 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $31.36 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $30.04 | 2019-2020 | |
| Biogen, INC. | $27.87 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $26.41 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $24.18 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.77 | 2019 | |
| Sk Life Science, INC. | $18.48 | 2020 | |
| Neurocrine Biosciences, INC. | $18.41 | 2019 | |
| Mallinckrodt Enterprises LLC | $17.08 | 2019 | |
| Medtronic Vascular, INC. | $16.81 | 2020 | |
| Bausch Health US, LLC | $16.80 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.02 | 2019 | |
| Allergan, INC. | $14.66 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.20 | 2024 | Xarelto |
| Assertio Therapeutics, INC. | $13.09 | 2019 | |
| Strongbridge US INC. | $11.21 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.07 | 2019 | |
| Genzyme Corporation | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Culligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.